gdc
FDA Approvals, News & UpdatesLymphomaNewsworthy

Calquence Newest Treatment Approved for Mantle-Cell Lymphoma

In October 2017, the FDA accelerated the approval of Calquence for the treatment of adults with mantle-cell lymphoma who have received at least 1 previous therapy.
December 2017 Vol 3 No 6

On October 31, 2017, the FDA accelerated the approval of Calquence (acalabrutinib; from AstraZeneca) for the treatment of adults with mantle-cell lymphoma who have received at least 1 previous therapy. Mantle-cell lymphoma is a rare and fast-growing type of non-Hodgkin lymphoma.

“Mantle cell lymphoma is a particularly aggressive cancer,” said Richard Pazdur, MD, Director of the FDA’s Oncology Center of Excellence. “For patients who have not responded to treatment or have relapsed, Calquence provides a new treatment option that has shown high rates of response for some patients in initial studies.”

This approval was based on a clinical trial of patients with mantle-cell lymphoma that showed that 81% of patients who received Calquence had a complete or partial response to this drug. Serious side effects with Calquence include bleeding, infections, and irregular heartbeat. Women who breastfeed should not take this drug. In addition, new cases of cancer occurred in some patients who used Calquence.

Recommended For You
FDA Approvals, News & Updates
FDA NEWs
On August 5, 2020, the FDA accelerated the approval of Blenrep (belantamab mafodotin-blmf; from GlaxoSmithKline), a B-cell maturation antigen (BCMA)-directed antibody and microtubule inhibitor conjugate, for the treatment of adults with relapsed or refractory multiple myeloma who have received at least 4 previous therapies, including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent.
Lymphoma
Yescarta Leads to Long-Term Responses in Patients with Advanced Follicular Lymphoma or Marginal-Zone Lymphoma
By Wayne Kuznar
A total of 80% of patients with relapsed (coming back) or refractory (not responding to therapy) slow-growing (indolent) non-Hodgkin lymphoma (NHL)—including patients with follicular lymphoma or marginal-zone lymphoma (MZL)—achieved a complete response (no sign of cancer) to Yescarta (axicabtagene ciloleucel), an anti-CD19 CAR T-cell therapy.
Lymphoma
Keytruda New Standard of Care for Relapsed or Refractory Classical Hodgkin Lymphoma
By Phoebe Starr
Treatment with the PD-1 inhibitor Keytruda (permbrolizumab) significantly extended progression-free survival (PFS) in patients with classical Hodgkin lymphoma compared with standard treatment with Adcetris (brentuximab vedotin), according to the results of the phase 3 KEYNOTE-204 clinical trial reported at the ASCO 2020 virtual annual meeting.
Lymphoma
Keytruda Immunotherapy Prolongs Survival in Patients with Relapsed or Refractory Hodgkin Lymphoma
By Phoebe Starr
Using the immunotherapy Keytruda (pembrolizumab), a PD-1 inhibitor, prolongs the time without disease progression in patients with relapsed (coming back) or refractory (not responding to treatment) classical Hodgkin lymphoma compared with the current standard of therapy of Adcetris (brentuximab vedotin), an antibody–drug conjugate.
Last modified: January 16, 2018

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.

Country